REDWOOD CITY, Calif., Feb. 3, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that its scientists successfully surveyed expression of the whole human transcriptome using next-generation DNA sequencing technology developed by Illumina, Inc., to test hypotheses for biomarker discovery in archived tumor and normal breast tissue samples. The study identified hundreds of coding and non-coding transcripts that are differentially expressed in tumor versus normal, non-cancerous breast tissue, including a subset of genes statistically associated with the recurrence of breast cancer. Additionally, novel candidate biomarkers from outside of the known protein-coding regions of the genome were discovered to be associated with recurrence of breast cancer. The findings were presented today at the 12th Annual Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Fla.
"These results demonstrate the use of next-generation sequencing of formalin-fixed tissue to accelerate testing of hypotheses for biomarker discovery," said Joffre Baker, Chief Scientific Officer at Genomic Health. "Our long-term goal for this and future studies is to validate the findings with large, well-designed clinical trials in an effort to connect either gene mutations or expression profiles to clinical outcomes and provide additional personalized information to physicians and patients beyond that already available through the use of Oncotype DX®."
The study was designed to compare gene expression profiles between 12 normal and 12 tumor formalin-fixed (FFPE) breast specimens – all of which were 10-13 years old. Each sample, on average, yielded 19 million base pairs of DNA with approximately 85 percent mapping to unique sites in the human genome. Further analysis showed that 3,584 coding genes were differentially expr
|SOURCE Genomic Health, Inc.|
Copyright©2010 PR Newswire.
All rights reserved